about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

So­bi's high-pri­or­i­ty rare dis­ease drug runs in­to a wall at EMA

5 years ago
Pharma
FDA+

FBI crack­down on Chi­na’s R&D es­pi­onage in­ten­si­fies with new ar­rests and one fugi­tive in San Fran­cis­co

5 years ago
China

Hous­ton’s huge R&D hub takes cen­ter stage in feds’ cam­paign to clip Chi­na’s ties to re­searchers, IP theft

5 years ago
China

Fast fol­low: EQRx en­gi­neers $410M-plus worth of deals to CDK4/6, EGFR drugs

5 years ago
Deals

Ayahuas­ca in­spires an­oth­er biotech start­up at ATAI; My­lan TB drug gets green light in In­dia

5 years ago
News Briefing

'Miss­ing link': Bay­er, Morn­ing­side help cat­a­pult a new kind of de­liv­ery tech to cell and gene ther­a­py

5 years ago
Financing
Startups

Can ful­ly shut­ting down the es­tro­gen re­cep­tor make a dif­fer­ence in breast can­cer? Ole­ma scores $54M to find out in ...

5 years ago
Financing

Covid-19 roundup: Top an­a­lyst pokes hole in As­traZeneca/Ox­ford da­ta while sci­en­tists tam­per hope for fast roll­out

5 years ago
Coronavirus

Juno/WuX­i's cell ther­a­py ven­ture buys out sol­id tu­mor play­er in Chi­na, gain­ing a dis­cov­ery en­gine and por­tend­ing more ...

5 years ago
Deals
China

GSK, Ger­many push coro­n­avirus-fo­cused mR­NA play­er Cure­Vac's lat­est round to $640M

5 years ago
Financing
Coronavirus

Roche part­ners on a slate of Jnana's im­munol­o­gy, neu­rol­o­gy tar­gets, re­ward­ing its faith in the SLC trans­porter class

5 years ago
Deals

As­traZeneca, Ox­ford re­searchers cham­pi­on a one-two punch against Covid-19 in first hu­man study

5 years ago
R&D
Coronavirus

GSK in­jects $293M cash in­to Cure­Vac, forg­ing a deal to de­vel­op new mR­NA vac­cines and an­ti­bod­ies

5 years ago
Deals

UK biotech rock­ets up on Covid-19 'break­through' for in­haled in­ter­fer­on be­ta — can its small study live up to the ...

5 years ago
R&D
Coronavirus

BMS gets the ball rolling on liso-cel in Eu­rope; BeiGene files Chi­na NDA for in-house PARP drug

5 years ago
News Briefing

Chi­na's CRO pow­er­house Tigermed to seek $1B IPO in Hong Kong — re­port

5 years ago
Financing
China

Covid-19 roundup: EU looks to pre-or­der vac­cines from Mod­er­na, Sanofi, J&J, BioN­Tech, Cure­Vac — re­port

5 years ago
Coronavirus

Covid-19 roundup: Rus­sia hack­ers tar­get US, UK vac­cine and drug re­searchers; Fau­ci fires back at White House cam­paign ...

5 years ago
Coronavirus

A neu­ro­sur­geon spent the past 30 years de­vel­op­ing a neoanti­gen tu­mor vac­cine. Now he has $112M for a piv­otal test

5 years ago
Financing

Re­lay reaps $400M IPO wind­fall af­ter draw­ing the cur­tain on mo­tion-based drug de­sign pipeline

5 years ago
Financing

Who are the women blaz­ing trails in bio­phar­ma R&D and lead­ing the fight against Covid-19? Nom­i­nate them for ...

5 years ago
People
Editor's note

Covid-19 roundup: Vac­cine by end of 2020? Ken Fra­zier warns hype do­ing 'grave dis­ser­vice'

5 years ago
Coronavirus

J&J nabs new OK for IL-23 drug Trem­fya; Mer­ck KGaA spin­out ups Se­ries A tal­ly to €20.1M

5 years ago
News Briefing

Bil­lions of dol­lars worth of SPACs are rid­ing on the biotech IPO boom

5 years ago
Financing
First page Previous page 70717273747576 Next page Last page
A service from the Financial Times